γ-Secretase as a Target for Alzheimer’s Disease
Author:
- 1 January 2012
- book chapter
- Published by Elsevier
- Vol. 64, 127-153
Abstract
No abstract availableKeywords
This publication has 102 references indexed in Scilit:
- Phenylpiperidine‐type γ‐secretase modulators target the transmembrane domain 1 of presenilin 1The EMBO Journal, 2011
- Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's DiseaseNeuron, 2010
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled TrialJAMA, 2009
- Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer diseaseEMBO Reports, 2008
- Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer DiseaseArchives of Neurology, 2008
- Signal Peptide Peptidase: Biochemical Properties and Modulation by Nonsteroidal Antiinflammatory DrugsBiochemistry, 2006
- Purification and Characterization of the Human γ-Secretase ComplexBiochemistry, 2004
- Reconstitution of γ-secretase activityNature Cell Biology, 2003
- L-685,458, an Aspartyl Protease Transition State Mimic, Is a Potent Inhibitor of Amyloid β-Protein Precursor γ-Secretase ActivityBiochemistry, 2000
- Presenilin 1 is required for Notch 1 and Dll1 expression in the paraxial mesodermNature, 1997